IP Library Granted Patent US 9,499,480
Granted Patent B2
US 9,499,480 · App. 14/246,894 · Granted Nov 22, 2016

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Inventors: Xianqi Kong (Dollard-des-Ormeaux, CA); Mohamed Atfani (Laval, CA); Benoit Bachand (St-Laurent, CA); Abderrahim Bouzide (Laval, CA); Stephane Ciblat (Montreal, CA); Sophie Levesque (Mirabel, CA); David Migneault (Laval, CA); Isabelle Valade (Laval, CA); Xinfu Wu (Laval, CA); Daniel Delorme (St-Lazare, CA)
Assignee: BHI Limited Partnership
C07C309/24A61K47/48023A61K47/48092C07C309/15C07C309/18C07C309/19C07D207/16C07D209/20C07D217/24C07D233/64C07D285/36C07D285/38C07D291/02C07D323/02C07D333/24C07H7/02C07H15/12C07J9/005C07K5/0606C07K5/06026C07K5/06052C07K5/06069C07K5/06086C07K5/081C07K5/0806C12P11/00C12P13/001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,480
App. No.
14/246,894
Granted
Nov 22, 2016
Kind
B2
Abstract

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

Claims (21)

1. A compound of Formula XII:

wherein,

D is a carbonyl or a substituted methylene group; and

X is selected from 0, NH, and S;

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1 , wherein D is a carbonyl.

3. The compound of claim 1 , wherein D is a substituted methylene group.

4. The compound of claim 1 , wherein X is an oxygen atom.

5. The compound of claim 1 , wherein Xis a NH group.

6. The compound of claim 1 , wherein X is a sulfur atom.

7. The compound claim 1 , wherein said compound is of Formula XII-A:

wherein,

R 14 is a substituted or unsubstituted group selected from C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 3 -C 15 cycloalkyl, C 3 -C 15 heterocycloalkyl, C 6 -C 15 aryl, and C 5 -C 15 heteroaryl;

or a pharmaceutically acceptable salt or solvate thereof.

8. The compound of claim 7 , wherein said R 14 is a substituted or unsubstituted C 1 -C 12 alkyl group.

9. The compound of claim 8 , wherein said R 14 is a substituted or unsubstituted C 1 -C 6 alkyl group.

10. A pharmaceutical composition comprising a compound of claim 1 together with a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10 which is suitable for oral administration.

12. The pharmaceutical composition of claim 10 , which is in the form of a hard shell gelatin capsule, soft shell gelatin capsule, cachet, pill, tablet, lozenge, powder, granule, pellet, dragee, which is optionally enteric coated, a solution, an aqueous liquid suspension, a non-aqueous liquid suspension, an oil-in-water liquid emulsion, a water-in-oil liquid emulsion, an elixir, a syrup, or a pastille.

13. A compound selected from:

or a pharmaceutically acceptable salt or solvate thereof.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2017
From: THALLION PHARMACEUTICALS INC.
To: BELLUS HEALTH INC.
Reel/Frame 042446/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2017
From: BHI LIMITED PARTNERSHIP
To: THALLION PHARMACEUTICALS INC.; BELLUS HEALTH INC.
Reel/Frame 042446/0403 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2014
From: KONG, XIANQI; ATFANI, MOHAMED; BACHAND, BENOIT; BOUZIDE, ABDERRAHIM; CIBLAT, STEPHANE; LEVESQUE, SOPHIE; MIGNEAULT, DAVID; VALADE, ISABELLE; WU, XINFU; DELORME, DANIEL
To: NEUROCHEM (INTERNATIONAL) LIMITED
Reel/Frame 032755/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2014
From: BELLUS HEALTH (INTERNATIONAL) LIMITED
To: BELLUS HEALTH INC.
Reel/Frame 032755/0228 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2014
From: BELLUS HEALTH INC.
To: BHI LIMITED PARTNERSHIP
Reel/Frame 032755/0258 →
CHANGE OF NAME Recorded Apr 25, 2014
From: NEUROCHEM (INTERNATIONAL) LIMITED
To: BELLUS HEALTH (INTERNATIONAL) LIMITED
Reel/Frame 032763/0361 →
Continuity (4)
Continuation 11871639 · Oct 12, 2007
Provisional Application 60851039 · Oct 12, 2006
Provisional Application 60911459 · Apr 12, 2007
Related Publication 20140220122A1 · Aug 7, 2014